Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements are non-label information (cost, bulk purchasing logistics, online purchase, anxiety/stress). Several drug-knowledge claims are not explicitly supported by the provided label excerpts as written. Key label-based safety and administration details are omitted.
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
Supported by provided label naming context: Drug listed as LIPITOR with active ingredient atorvastatin calcium; and label refers to LIPITOR and atorvastatin/atorvastatin calcium in clinical pharmacology mechanism section.
Lipitor is a statin medication.
Supported by label class language: 'HMG-CoA reductase inhibitors (statins)' appears in drug interactions section.
Unsupported Statements
Lipitor helps lower cholesterol levels in the blood.
Not explicitly stated in provided excerpts as written; while label discusses reducing LDL-C/total-C in indications and studies, the claim 'helps lower cholesterol levels in the blood' is not directly supported as a standalone statement in the provided text.
Lipitor works by inhibiting the production of cholesterol in the liver.
The provided mechanism describes inhibition of HMG-CoA reductase and effects on circulating lipids/atherosclerosis, but the 'inhibiting the production of cholesterol in the liver' phrasing is not explicitly supported in the provided excerpts.
By reducing LDL cholesterol, Lipitor reduces low-density lipoprotein (LDL) or 'bad' cholesterol in the blood.
While LDL-C reduction is addressed in indications, the statement repeats a synonym explanation ('bad' cholesterol) and 'in the blood' framing that is not explicitly supported in the provided excerpts.
By reducing LDL cholesterol, Lipitor helps prevent the buildup of plaque in the arteries.
The label links elevated plasma cholesterol/LDL-C/apo B with atherosclerosis, but the specific causal phrasing 'reducing LDL cholesterol prevents plaque buildup in the arteries' is not explicitly stated in provided excerpts.
Preventing plaque buildup in the arteries can lead to reduced risk of heart disease and stroke.
Label provides risk reductions for MI/stroke and revascularization/angina, but it does not state the intermediate 'preventing plaque buildup' pathway as written.
The average cost of a 30-day supply of Lipitor in the United States is around $140.
No pricing/cost information appears in the provided FDA label excerpts.
Buying Lipitor in bulk can provide a lower cost per pill compared to buying smaller quantities.
No cost/bulk purchasing statements appear in the provided FDA label excerpts.
Buying in bulk can eliminate the need to constantly refill a prescription.
No refill frequency or purchasing logistics appear in the provided FDA label excerpts.
Patients who bought Lipitor in bulk saved an average of 20% to 30% compared to those who bought a smaller quantity.
No study, survey, or savings figures appear in the provided FDA label excerpts.
If a 30-day supply of Lipitor costs $140, then the total cost for 30 days is $140.
No such cost premise is supported by the FDA label excerpts.
If a 90-day supply of Lipitor costs $420, then the total cost for 90 days is $420.
No such cost premise is supported by the FDA label excerpts.
A 30-day supply priced at $140 corresponds to a cost per pill of $1.67.
No pill-count/cost-per-pill calculations or pill count are provided in the label excerpts.
A 90-day supply priced at $420 corresponds to a cost per pill of $1.33.
No pill-count/cost-per-pill calculations or pill count are provided in the label excerpts.
Buying in bulk can reduce stress and anxiety related to managing cholesterol levels.
No psychosocial outcome or anxiety/stress statements appear in the provided FDA label excerpts.
A prescription is needed to buy Lipitor.
No prescribing/dispensing regulatory requirement statement appears in the provided FDA label excerpts.
Lipitor can be bought online from reputable pharmacies.
No guidance on online purchasing appears in the provided FDA label excerpts.
Contradictions
Important Omissions
Boxed-warning-equivalent safety context and key warnings/precautions (e.g., pregnancy harm contraindication, skeletal muscle/myopathy/rhabdomyolysis precautions, liver dysfunction cautions) are not mentioned while the response focuses on non-label topics.
Importance:
High
Dosage and administration instructions from the label (starting dose, once-daily dosing timing, dosage range, administration with/without food) are not provided.
Importance:
Moderate
Indication limitations and risk-factor context from label (diet adjunct, multiple risk factor/CHD population wording, specified cardiovascular risk reductions) are not described with label precision.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response omits critical label safety information (notably pregnancy contraindication and major warnings/precautions) and includes substantial non-label content that could distract from appropriate safe use. No direct contraindication conflict is identified in the provided claims, but the overall label alignment is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most statements are not supported by the provided FDA label excerpts (cost/bulk purchasing/online purchase/psychosocial claims). Several mechanism/plaque pathway statements are not explicitly supported as written by the provided label text.
Suggested Improvement
Restrict claims to label-supported information: explicitly cite the label’s stated indications and risk reductions (MI, stroke, revascularization/angina), and use the label’s mechanism phrasing (HMG-CoA reductase inhibition) without adding unsupported intermediate statements. Include key safety elements from the label (pregnancy contraindication and skeletal muscle/liver warnings) and omit pricing/purchasing/logistics and psychosocial assertions not present in the label.